טוען...
Targeted treatments in advanced renal cell carcinoma: focus on axitinib
Antiangiogenesis options have evolved rapidly in the last few years, with an increasing number of agents currently approved by the US Food and Drug Administration and European Medicines Agency. Angiogenesis inhibitors have been shown to be very effective for the treatment of metastatic renal cancer...
שמור ב:
| Main Authors: | , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove Medical Press
2014
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3977458/ https://ncbi.nlm.nih.gov/pubmed/24715765 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PGPM.S37098 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|